作者：
Kendra L,Sweet [1]
;
Jorge E,Cortes [2]
;
Jane F,Apperley [3]
;
Mel,Mann [4]
;
Michael J,Mauro [5]
;
Vivian G,Oehler [6]
;
Cristina,Ruiz [4]
;
Charles A,Schiffer [7]
;
Lori A,Ehrlich [8]
;
Gulsum E,Pamuk [8]
;
Joseph,Wynne [8]
;
Gautam U,Mehta [8]
;
Olanrewaju O,Okusanya [8]
;
R Angelo,de Claro [8]
;
Marc R,Theoret [9]
;
B Douglas,Smith [10]
;
Kelly J,Norsworthy [8]
作者单位：
Moffitt Cancer Center, Tampa, Florida.
[1]
Georgia Cancer Center, Augusta University, Augusta, Georgia.
[2]
Centre for Haematology, Imperial College, London, United Kingdom.
[3]
Patient Advocate, Jonesboro, Georgia.
[4]
Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York City, New York.
[5]
Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, Washington.
[6]
Department of Hematology-Oncology, Karmanos Cancer Center at Wayne State University, Detroit, Michigan.
[7]
Center for Drug Evaluation and Research, FDA, Washington, District of Columbia.
[8]
Oncology Center of Excellence, FDA, Washington, District of Columbia.
[9]
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
[10]
DOI
10.1158/1078-0432.CCR-23-3234
PMID
38178776
发布时间
2024-07-06
换一批
换一批
